CA2533926C

CA2533926C - Methods and compositions for producing antigenic responses

Methods and compositions for producing antigenic responses Download PDF

Info

Publication number: CA2533926C
Authority: CA; Canada
Prior art keywords: cells; antigen; adenosine receptor; cell; adenosine
Prior art date: 2003-07-31
Legal status : Expired - Fee Related

Application number

CA2533926A

Other languages

English (en)

French (fr)

Other versions

CA2533926A1 (en

Inventor

Constance Neely Wilson

Paul Borron

Current Assignee

Endacea Inc

Original Assignee

Endacea Inc

Priority date

2003-07-31

Filing date

2004-07-30

Publication date

2013-10-15

2004-07-30 Application filed by Endacea Inc filed Critical Endacea Inc

2005-03-24 Publication of CA2533926A1 publication Critical patent/CA2533926A1/en

2013-10-15 Application granted granted Critical

2013-10-15 Publication of CA2533926C publication Critical patent/CA2533926C/en

2024-07-30 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 108
230000004044 response Effects 0.000 title claims abstract description 50
230000000890 antigenic effect Effects 0.000 title claims abstract description 33
239000000203 mixture Substances 0.000 title abstract description 112
101150007969 ADORA1 gene Proteins 0.000 claims abstract description 163
239000000427 antigen Substances 0.000 claims abstract description 91
108091007433 antigens Proteins 0.000 claims abstract description 89
102000036639 antigens Human genes 0.000 claims abstract description 89
206010028980 Neoplasm Diseases 0.000 claims abstract description 60
239000003795 chemical substances by application Substances 0.000 claims abstract description 60
210000004027 cell Anatomy 0.000 claims description 138
210000004443 dendritic cell Anatomy 0.000 claims description 48
230000028993 immune response Effects 0.000 claims description 27
210000000130 stem cell Anatomy 0.000 claims description 26
230000037452 priming Effects 0.000 claims description 25
231100000433 cytotoxic Toxicity 0.000 claims description 23
230000001472 cytotoxic effect Effects 0.000 claims description 23
230000011664 signaling Effects 0.000 claims description 17
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 16
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 16
239000002299 complementary DNA Substances 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 16
239000003379 purinergic P1 receptor agonist Substances 0.000 claims description 16
230000007812 deficiency Effects 0.000 claims description 15
239000002773 nucleotide Substances 0.000 claims description 15
125000003729 nucleotide group Chemical group 0.000 claims description 15
108020004999 messenger RNA Proteins 0.000 claims description 12
108050000203 Adenosine receptors Proteins 0.000 claims description 11
102000009346 Adenosine receptors Human genes 0.000 claims description 11
230000002708 enhancing effect Effects 0.000 claims description 11
238000002347 injection Methods 0.000 claims description 10
239000007924 injection Substances 0.000 claims description 10
230000004043 responsiveness Effects 0.000 claims description 10
229940122614 Adenosine receptor agonist Drugs 0.000 claims description 7
238000000338 in vitro Methods 0.000 claims description 7
230000015788 innate immune response Effects 0.000 claims description 4
230000033289 adaptive immune response Effects 0.000 claims description 3
ZDYTXFAMUFCZFA-UHFFFAOYSA-N acetyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)=O ZDYTXFAMUFCZFA-UHFFFAOYSA-N 0.000 claims 1
QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 claims 1
QGVLYPPODPLXMB-UBTYZVCOSA-N phorbol group Chemical group O[C@@]12CC(=C[C@@H]3[C@@]([C@@H]2C=C(C1=O)C)([C@@H]([C@H]([C@@]1([C@H]3C1(C)C)O)O)C)O)CO QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 claims 1
210000000612 antigen-presenting cell Anatomy 0.000 abstract description 114
230000003213 activating effect Effects 0.000 abstract description 39
201000011510 cancer Diseases 0.000 abstract description 15
238000003384 imaging method Methods 0.000 abstract description 14
208000015181 infectious disease Diseases 0.000 abstract description 12
230000002458 infectious effect Effects 0.000 abstract description 7
238000009007 Diagnostic Kit Methods 0.000 abstract description 4
230000002950 deficient Effects 0.000 abstract description 4
230000006872 improvement Effects 0.000 abstract description 3
238000002648 combination therapy Methods 0.000 abstract description 2
238000003745 diagnosis Methods 0.000 abstract description 2
238000004393 prognosis Methods 0.000 abstract description 2
230000004083 survival effect Effects 0.000 abstract 1
210000001616 monocyte Anatomy 0.000 description 43
238000011282 treatment Methods 0.000 description 43
238000009472 formulation Methods 0.000 description 34
108090000623 proteins and genes Proteins 0.000 description 34
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 30
102000004169 proteins and genes Human genes 0.000 description 29
150000001875 compounds Chemical class 0.000 description 28
239000003446 ligand Substances 0.000 description 26
230000027455 binding Effects 0.000 description 23
238000001943 fluorescence-activated cell sorting Methods 0.000 description 20
239000000443 aerosol Substances 0.000 description 18
239000002245 particle Substances 0.000 description 17
239000002126 C01EB10 - Adenosine Substances 0.000 description 16
108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 16
229960005305 adenosine Drugs 0.000 description 16
238000000586 desensitisation Methods 0.000 description 16
210000002540 macrophage Anatomy 0.000 description 16
230000003013 cytotoxicity Effects 0.000 description 15
231100000135 cytotoxicity Toxicity 0.000 description 15
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 14
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
239000002158 endotoxin Substances 0.000 description 14
239000003380 propellant Substances 0.000 description 14
229960005486 vaccine Drugs 0.000 description 14
-1 IL-113 Proteins 0.000 description 13
239000003814 drug Substances 0.000 description 13
239000012528 membrane Substances 0.000 description 13
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
239000007787 solid Substances 0.000 description 13
239000000126 substance Substances 0.000 description 13
239000013543 active substance Substances 0.000 description 12
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 12
229960004316 cisplatin Drugs 0.000 description 12
238000005516 engineering process Methods 0.000 description 12
239000008194 pharmaceutical composition Substances 0.000 description 12
102000004127 Cytokines Human genes 0.000 description 11
108090000695 Cytokines Proteins 0.000 description 11
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 11
108090001005 Interleukin-6 Proteins 0.000 description 11
102000004889 Interleukin-6 Human genes 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
229940100601 interleukin-6 Drugs 0.000 description 11
239000007788 liquid Substances 0.000 description 11
108700018351 Major Histocompatibility Complex Proteins 0.000 description 10
239000000872 buffer Substances 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
229920006008 lipopolysaccharide Polymers 0.000 description 10
210000004698 lymphocyte Anatomy 0.000 description 10
239000000843 powder Substances 0.000 description 10
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 9
102000055025 Adenosine deaminases Human genes 0.000 description 9
102000000589 Interleukin-1 Human genes 0.000 description 9
108010002352 Interleukin-1 Proteins 0.000 description 9
230000004913 activation Effects 0.000 description 9
239000004480 active ingredient Substances 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
230000007402 cytotoxic response Effects 0.000 description 9
230000006870 function Effects 0.000 description 9
239000002502 liposome Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000002671 adjuvant Substances 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
229940079593 drug Drugs 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
210000005259 peripheral blood Anatomy 0.000 description 8
239000011886 peripheral blood Substances 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
150000003839 salts Chemical class 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
238000002255 vaccination Methods 0.000 description 8
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
239000000969 carrier Substances 0.000 description 7
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 7
239000012636 effector Substances 0.000 description 7
239000003623 enhancer Substances 0.000 description 7
230000036039 immunity Effects 0.000 description 7
230000019491 signal transduction Effects 0.000 description 7
239000000725 suspension Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
238000001890 transfection Methods 0.000 description 7
230000002476 tumorcidal effect Effects 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
102000034286 G proteins Human genes 0.000 description 6
108091006027 G proteins Proteins 0.000 description 6
102000004388 Interleukin-4 Human genes 0.000 description 6
108090000978 Interleukin-4 Proteins 0.000 description 6
108010003541 Platelet Activating Factor Proteins 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
230000003281 allosteric effect Effects 0.000 description 6
239000000367 immunologic factor Substances 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
229940028885 interleukin-4 Drugs 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
238000001638 lipofection Methods 0.000 description 6
230000035800 maturation Effects 0.000 description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
102000019034 Chemokines Human genes 0.000 description 5
108010012236 Chemokines Proteins 0.000 description 5
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
108091000058 GTP-Binding Proteins 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
206010060862 Prostate cancer Diseases 0.000 description 5
208000000236 Prostatic Neoplasms Diseases 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
229940121359 adenosine receptor antagonist Drugs 0.000 description 5
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical class F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 5
230000004069 differentiation Effects 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000004520 electroporation Methods 0.000 description 5
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
210000003979 eosinophil Anatomy 0.000 description 5
108700014844 flt3 ligand Proteins 0.000 description 5
239000008187 granular material Substances 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000002955 immunomodulating agent Substances 0.000 description 5
238000002372 labelling Methods 0.000 description 5
210000000265 leukocyte Anatomy 0.000 description 5
238000005259 measurement Methods 0.000 description 5
244000052769 pathogen Species 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
239000002243 precursor Substances 0.000 description 5
239000000296 purinergic P1 receptor antagonist Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
230000004936 stimulating effect Effects 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
239000003053 toxin Substances 0.000 description 5
231100000765 toxin Toxicity 0.000 description 5
108700012359 toxins Proteins 0.000 description 5
RIRGCFBBHQEQQH-SSFGXONLSA-N (-)-n6-(2-phenylisopropyl)adenosine Chemical compound C([C@@H](C)NC=1C=2N=CN(C=2N=CN=1)[C@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)C1=CC=CC=C1 RIRGCFBBHQEQQH-SSFGXONLSA-N 0.000 description 4
241000271566 Aves Species 0.000 description 4
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
238000011510 Elispot assay Methods 0.000 description 4
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
108010074328 Interferon-gamma Proteins 0.000 description 4
102000003814 Interleukin-10 Human genes 0.000 description 4
108090000174 Interleukin-10 Proteins 0.000 description 4
102000003815 Interleukin-11 Human genes 0.000 description 4
108090000177 Interleukin-11 Proteins 0.000 description 4
102000013462 Interleukin-12 Human genes 0.000 description 4
108010065805 Interleukin-12 Proteins 0.000 description 4
102000003816 Interleukin-13 Human genes 0.000 description 4
108090000176 Interleukin-13 Proteins 0.000 description 4
102000003812 Interleukin-15 Human genes 0.000 description 4
108090000172 Interleukin-15 Proteins 0.000 description 4
102000049772 Interleukin-16 Human genes 0.000 description 4
101800003050 Interleukin-16 Proteins 0.000 description 4
102000013691 Interleukin-17 Human genes 0.000 description 4
108050003558 Interleukin-17 Proteins 0.000 description 4
102000000646 Interleukin-3 Human genes 0.000 description 4
108010002386 Interleukin-3 Proteins 0.000 description 4
102100039897 Interleukin-5 Human genes 0.000 description 4
108010002616 Interleukin-5 Proteins 0.000 description 4
102100021592 Interleukin-7 Human genes 0.000 description 4
108010002586 Interleukin-7 Proteins 0.000 description 4
102000004890 Interleukin-8 Human genes 0.000 description 4
108090001007 Interleukin-8 Proteins 0.000 description 4
102000000585 Interleukin-9 Human genes 0.000 description 4
108010002335 Interleukin-9 Proteins 0.000 description 4
102000008072 Lymphokines Human genes 0.000 description 4
108010074338 Lymphokines Proteins 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
102000018697 Membrane Proteins Human genes 0.000 description 4
108010052285 Membrane Proteins Proteins 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
241000286209 Phasianidae Species 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 4
101710097161 Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 4
238000013459 approach Methods 0.000 description 4
239000002585 base Substances 0.000 description 4
239000011324 bead Substances 0.000 description 4
230000008512 biological response Effects 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
229940029030 dendritic cell vaccine Drugs 0.000 description 4
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
229960003957 dexamethasone Drugs 0.000 description 4
201000010099 disease Diseases 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
229940121354 immunomodulator Drugs 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
229940076144 interleukin-10 Drugs 0.000 description 4
229940074383 interleukin-11 Drugs 0.000 description 4
229940117681 interleukin-12 Drugs 0.000 description 4
229940076264 interleukin-3 Drugs 0.000 description 4
229940100602 interleukin-5 Drugs 0.000 description 4
229940100994 interleukin-7 Drugs 0.000 description 4
229940096397 interleukin-8 Drugs 0.000 description 4
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
229940118526 interleukin-9 Drugs 0.000 description 4
208000028867 ischemia Diseases 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
229920002521 macromolecule Polymers 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
239000002287 radioligand Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
208000029462 Immunodeficiency disease Diseases 0.000 description 3
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
239000012124 Opti-MEM Substances 0.000 description 3
241000149788 Pseudophryne major Species 0.000 description 3
108010073443 Ribi adjuvant Proteins 0.000 description 3
206010052779 Transplant rejections Diseases 0.000 description 3
229920000392 Zymosan Polymers 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000000556 agonist Substances 0.000 description 3
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 3
229960000623 carbamazepine Drugs 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000007969 cellular immunity Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
229960000975 daunorubicin Drugs 0.000 description 3
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
230000008260 defense mechanism Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
229960002986 dinoprostone Drugs 0.000 description 3
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
229960004679 doxorubicin Drugs 0.000 description 3
231100000655 enterotoxin Toxicity 0.000 description 3
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
230000004727 humoral immunity Effects 0.000 description 3
230000007954 hypoxia Effects 0.000 description 3
230000003053 immunization Effects 0.000 description 3
239000003022 immunostimulating agent Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
210000001865 kupffer cell Anatomy 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
150000002617 leukotrienes Chemical class 0.000 description 3
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
210000000274 microglia Anatomy 0.000 description 3
229960001156 mitoxantrone Drugs 0.000 description 3
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
201000006417 multiple sclerosis Diseases 0.000 description 3
210000000822 natural killer cell Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
229940094443 oxytocics prostaglandins Drugs 0.000 description 3
239000013641 positive control Substances 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
150000003180 prostaglandins Chemical class 0.000 description 3
239000003909 protein kinase inhibitor Substances 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
CHMUHOFITZIING-XNIJJKJLSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-2-cyclohexyl-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(C2CCCCC2)O[C@H](CO)[C@@H](O)[C@H]1O CHMUHOFITZIING-XNIJJKJLSA-N 0.000 description 2
XSMYYYQVWPZWIZ-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NC3CCCC3)=C2N=C1 XSMYYYQVWPZWIZ-IDTAVKCVSA-N 0.000 description 2
FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
ZUEJJBKBTNSMGJ-XNIJJKJLSA-N 4-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]benzenesulfonic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC=3C=CC(=CC=3)S(O)(=O)=O)=C2N=C1 ZUEJJBKBTNSMGJ-XNIJJKJLSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
241000272517 Anseriformes Species 0.000 description 2
101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
229920002498 Beta-glucan Polymers 0.000 description 2
102100023702 C-C motif chemokine 13 Human genes 0.000 description 2
101710112613 C-C motif chemokine 13 Proteins 0.000 description 2
102100023703 C-C motif chemokine 15 Human genes 0.000 description 2
102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
102100036848 C-C motif chemokine 20 Human genes 0.000 description 2
102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
101710155834 C-C motif chemokine 7 Proteins 0.000 description 2
108010029697 CD40 Ligand Proteins 0.000 description 2
102100032937 CD40 ligand Human genes 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
108010078546 Complement C5a Proteins 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
101710146739 Enterotoxin Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000283086 Equidae Species 0.000 description 2
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
229930186217 Glycolipid Natural products 0.000 description 2
108700010013 HMGB1 Proteins 0.000 description 2
101150021904 HMGB1 gene Proteins 0.000 description 2
102000002812 Heat-Shock Proteins Human genes 0.000 description 2
108010004889 Heat-Shock Proteins Proteins 0.000 description 2
102100037907 High mobility group protein B1 Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 2
101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 2
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
108010063954 Mucins Proteins 0.000 description 2
102000015728 Mucins Human genes 0.000 description 2
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 2
PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
102100034437 Neurabin-2 Human genes 0.000 description 2
108091014434 Neurabin-2 Proteins 0.000 description 2
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
108010013639 Peptidoglycan Proteins 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102100026918 Phospholipase A2 Human genes 0.000 description 2
108010058864 Phospholipases A2 Proteins 0.000 description 2
108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
102100038358 Prostate-specific antigen Human genes 0.000 description 2
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
101710162629 Trypsin inhibitor Proteins 0.000 description 2
229940122618 Trypsin inhibitor Drugs 0.000 description 2
241000700605 Viruses Species 0.000 description 2
150000003838 adenosines Chemical class 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
230000003915 cell function Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000009137 competitive binding Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
239000003975 dentin desensitizing agent Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
229960001760 dimethyl sulfoxide Drugs 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
239000000147 enterotoxin Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229960002518 gentamicin Drugs 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
230000002584 immunomodulator Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
244000144972 livestock Species 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
238000002826 magnetic-activated cell sorting Methods 0.000 description 2
238000000691 measurement method Methods 0.000 description 2
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000003607 modifier Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
239000007764 o/w emulsion Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
238000003653 radioligand binding assay Methods 0.000 description 2
230000010410 reperfusion Effects 0.000 description 2
238000007493 shaping process Methods 0.000 description 2
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
238000000527 sonication Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
210000002536 stromal cell Anatomy 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
125000004964 sulfoalkyl group Chemical group 0.000 description 2
239000013589 supplement Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
230000002229 tumoristatic effect Effects 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
WOOIBJWFHSHPJN-UHFFFAOYSA-N 2h-triazolo[4,5-h]quinazoline Chemical compound C1=CC2=NNN=C2C2=NC=NC=C21 WOOIBJWFHSHPJN-UHFFFAOYSA-N 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
WBWFIUAVMCNYPG-BQYQJAHWSA-N 8-(3-chlorostyryl)caffeine Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C)C=1\C=C\C1=CC=CC(Cl)=C1 WBWFIUAVMCNYPG-BQYQJAHWSA-N 0.000 description 1
RILCIJYEMWKTHL-UHFFFAOYSA-N 8-[2-(3-isothiocyanatophenyl)ethenyl]-1,3,7-trimethylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C)C=1C=CC1=CC=CC(N=C=S)=C1 RILCIJYEMWKTHL-UHFFFAOYSA-N 0.000 description 1
GWRWCCQBSHBLSN-UHFFFAOYSA-N 8h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Chemical class N1=CN2NC=NC2=C2C=NN=C21 GWRWCCQBSHBLSN-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
MSJODEOZODDVGW-UHFFFAOYSA-N 9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine Chemical compound N=1N2C(N)=NC3=CC=C(Cl)C=C3C2=NC=1C1=CC=CO1 MSJODEOZODDVGW-UHFFFAOYSA-N 0.000 description 1
102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
244000036975 Ambrosia artemisiifolia Species 0.000 description 1
235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
229940123407 Androgen receptor antagonist Drugs 0.000 description 1
102100022987 Angiogenin Human genes 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
102000003916 Arrestin Human genes 0.000 description 1
108090000328 Arrestin Proteins 0.000 description 1
102000008081 Arrestins Human genes 0.000 description 1
108010074613 Arrestins Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
108091008875 B cell receptors Proteins 0.000 description 1
102100035526 B melanoma antigen 1 Human genes 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000759568 Corixa Species 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
102400001047 Endostatin Human genes 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
241000282324 Felis Species 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
108010000916 Fimbriae Proteins Proteins 0.000 description 1
108010040721 Flagellin Proteins 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000008924 GPCR kinases Human genes 0.000 description 1
108050000878 GPCR kinases Proteins 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
102000034354 Gi proteins Human genes 0.000 description 1
108091006101 Gi proteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000654734 Homo sapiens Septin-4 Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000002227 Interferon Type I Human genes 0.000 description 1
108010014726 Interferon Type I Proteins 0.000 description 1
102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
241000283953 Lagomorpha Species 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
102000034655 MIF Human genes 0.000 description 1
108060004872 MIF Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
108050008953 Melanoma-associated antigen Proteins 0.000 description 1
102000001621 Mucoproteins Human genes 0.000 description 1
108010093825 Mucoproteins Proteins 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
102000006478 Protein Phosphatase 2 Human genes 0.000 description 1
108010058956 Protein Phosphatase 2 Proteins 0.000 description 1
206010037075 Protozoal infections Diseases 0.000 description 1
241000287530 Psittaciformes Species 0.000 description 1
102000002294 Purinergic P2X Receptors Human genes 0.000 description 1
108010000836 Purinergic P2X Receptors Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
241000287231 Serinus Species 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
241000272534 Struthio camelus Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000036693 Thrombopoietin Human genes 0.000 description 1
108010041111 Thrombopoietin Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
102100039094 Tyrosinase Human genes 0.000 description 1
108060008724 Tyrosinase Proteins 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
208000008385 Urogenital Neoplasms Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
230000004721 adaptive immunity Effects 0.000 description 1
239000004479 aerosol dispenser Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000000961 alloantigen Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
108010072788 angiogenin Proteins 0.000 description 1
238000010171 animal model Methods 0.000 description 1
235000003484 annual ragweed Nutrition 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000009141 biological interaction Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000007469 bone scintigraphy Methods 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000012152 bradford reagent Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
235000006263 bur ragweed Nutrition 0.000 description 1
239000003710 calcium ionophore Substances 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000010367 cloning Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
235000003488 common ragweed Nutrition 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
238000011393 cytotoxic chemotherapy Methods 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011257 definitive treatment Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
230000008472 epithelial growth Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
231100000776 exotoxin Toxicity 0.000 description 1
239000002095 exotoxin Substances 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
239000004811 fluoropolymer Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
230000003325 follicular Effects 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
238000000227 grinding Methods 0.000 description 1
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
229940124736 hepatitis-B vaccine Drugs 0.000 description 1
UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
238000012737 microarray-based gene expression Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
229960005225 mifamurtide Drugs 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000003595 mist Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
229940051875 mucins Drugs 0.000 description 1
238000012243 multiplex automated genomic engineering Methods 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
239000002674 ointment Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000011472 radical prostatectomy Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
235000009736 ragweed Nutrition 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000000176 sodium gluconate Substances 0.000 description 1
235000012207 sodium gluconate Nutrition 0.000 description 1
229940005574 sodium gluconate Drugs 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000009168 stem cell therapy Methods 0.000 description 1
238000009580 stem-cell therapy Methods 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
231100000617 superantigen Toxicity 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
230000003614 tolerogenic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000032258 transport Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005135 veiled cell Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1